Business Wire

THALES

Share
Keeping Connectivity Within Reach, OPPO Launches Its First Smartwatch With Thales’ eSIM Solutions

OPPO, the world's leading smart device manufacturer, has selected Thales’ set of eSIM products and services for its OPPO Watch, the brand’s first smartwatch series with built-in cellular connectivity. The launch of the OPPO Watch marks a strategic step into the field of IoT for the company.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200906005025/en/

One of the most compelling features of the OPPO Watch is the eSIM-based cellular connectivity. Thales’ eSIM allows OPPO Watch users to enjoy a smoothly digital experience by activating a mobile subscription remotely and always stay connected without having to tether it to a mobile phone. Users can make voice calls or send messages at any time directly through the smartwatch, providing seamless connectivity during workouts or other situations where carrying a mobile phone is inconvenient. This smooth experience leverages Thales eSIM solutions to offer a full range of subscription services during the life cycle of the device.

By eliminating the need for an additional SIM card slot, Thales’ eSIM makes sleek mobile-connected smartwatches possible. Indeed it enables a thinner and lighter smartwatch design while freeing up more space for extra features such as up to 50 meter water resistance. It thereby helps OPPO fulfil its mission of elevating life through technological artistry.

The Thales embedded SIM has been qualified by all three China’s mobile operators allowing OPPO smartwatch users to select their mobile subscription from any of these operators.

“As OPPO's first foray into the wearable electronics market, the OPPO Watch marks a strategic step into the field of AIoT (Artificial IoT) for the company. Thanks to Thales' eSIM solutions that bring smartphone-level convenience to smartwatches, users can stay connected in a smarter and more efficient way without restrictions. We are looking forward to working with Thales again, given their leadership in eSIM and the success of our current partnership.”
Liu Bo, President of OPPO China

“The wearable segment is the second largest market for eSIM-compliant consumer electronics after smartphones. ABI Research forecasts that a total of 315 million cellular enabled wearables will have shipped by 2025. Smartwatch makers, in particular, are increasingly on-boarding eSIM connectivity in their flat-design devices to address new smartwatch-only use cases such as kids safety, sports and health monitoring...”
David McQueen, Director, Connected Consumer Devices, ABI Research Research

“Thales is honoured to provide a full suite of eSIM solutions for OPPO Watch. AIoT is one of OPPO’s key focuses aiming to bring customers seamless experiences to their daily life, including sport and health. Thales is OPPO’s key eSIM solutions partner, empowering them with instant connectivity for their consumer devices. We are proud to accompany OPPO on this journey and fully support their ambitions of providing their users with the best innovations available.”
Jérôme Bendell, Vice President of Thales North Asia and CEO of Thales in China

Thales is the world's leader in eSIM connectivity management with more than 200 eSIM management platforms awarded by mobile operators, operator alliances, MVNOs, automotive makers, and OEMs across all continents.

Related resources:
What is an eSIM: 6 illustrated answers infographic
4 ways to activate eSIM-capable consumer IoT devices dossier
Best practices for optimising eSIM adoption eBook
Innovative eSIM use cases such as prepaid offers for inbound travelers and family bundle dossier

About Thales

Thales (Euronext Paris: HO) is a global technology leader shaping the world of tomorrow today. The Group provides solutions, services and products to customers in the aeronautics, space, transport, digital identity and security, and defence markets. With 83,000 employees in 68 countries, Thales generated sales of €19 billion in 2019 (on a pro forma basis including Gemalto over 12 months).

Thales is investing in particular in digital innovations – connectivity, Big Data, artificial intelligence and cybersecurity – technologies that support businesses, organisations and governments in their decisive moments.

About Thales in China

Thales provides innovative solutions for the infrastructure that forms the backbone of China’s growth. The Group has been present in China for around 40 years and is the trusted partner for the Chinese aviation and urban rail transportation industries. In the meanwhile, from secure software to biometrics and encryption, Thales has successfully applied its advanced technology to mobile communication, banking, IoT and software monetization etc. Thales has 3 JVs and employs 2,300 people with offices located in 8 cities in China. Thales established R&D centers and Innovation Hubs in Beijing, Dalian and Hong Kong to provide innovative solutions for both China and international market.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

MSCI Announces Baer Pettit to Retire as President17.11.2025 13:00:00 CET | Press release

Additional senior leadership changes will drive growth in new client segments and products MSCI Inc. (NYSE: MSCI), a leading provider of critical decision support tools and services for the global investment community, announced that C.D. Baer Pettit, President and Chief Operating Officer (COO), and a member of the Board of Directors, has informed the company that he will retire next year after more than 25 years in senior leadership roles. Mr. Pettit will continue to serve as President and a Director until March 1, 2026, and will remain as an advisor to the company for a period of time to ensure a smooth transition. Mr. Pettit joined MSCI in 2000 and has served in numerous senior leadership roles, including heading Client Coverage, Marketing and Index. He was appointed COO in 2015 and President in 2017, overseeing all products and operations, and he joined the Board of Directors in 2023. “Baer has been my longtime business partner, and he has played a pivotal role in shaping MSCI’s st

AdvanCell Appoints Philina Lee, PhD as Chief Executive Officer to Lead US Expansion and Drive Global Growth17.11.2025 13:00:00 CET | Press release

Dr Lee is a seasoned biopharmaceutical executive with a proven track record of leading cross-functional teams to successfully develop and commercialize innovative therapies in oncology AdvanCell Pty Ltd (“AdvanCell”), a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, today announced the appointment of Philina Lee, PhD as Chief Executive Officer and member of the Board of Directors. Dr Lee will head AdvanCell’s US expansion, accelerating clinical, manufacturing, and partnership activities to advance lead clinical candidate 212Pb-ADVC001 and the company’s innovative radiopharmaceutical portfolio. She will assume her role from January 1, 2026, and will be based at the company’s new US headquarters near Boston/Cambridge, MA. “Philina brings a rare combination of global commercial leadership, deep radiopharmaceutical expertise, and an outstanding record of building high growth organizations and high-performance teams,” said Andrew Kay, C

Connections, Local Flavors, and Luxurious Experiences Top the 2026 Bacardi Cocktail Trends Report17.11.2025 13:00:00 CET | Press release

This year’s findings highlight a move towards more meaningful occasions, micro-indulgence, and storytelling cocktail experiences The five defining trends set to reshape cocktail culture and the spirits industry in 2026 are highlighted in the seventh annual Bacardi Cocktail Trends Report. The Report released by Bacardi Limited, the largest privately held international spirits company, in partnership with The Future Laboratory (TFL), draws on data from Bacardi-led and third-party research, consumer surveys, bartender interviews and TFL’s trend forecasting to uncover the forces shaping cocktail experiences, flavor innovation, and drinking culture in the year ahead. The Report also reveals the cocktails which are set to be the most popular in 2026 and trends for younger Legal Drinking Age (LDA) consumers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117678098/en/ The 7th annual Bacardi Cocktail Trends Report unveils what an

Arada to Acquire Majority Stake in £2.5bn Thameside West Development, Unlocking One of London’s Largest and Most Connected New Waterfront Neighbourhoods17.11.2025 12:58:00 CET | Press release

Arada, the UAE’s fastest-growing master developer, announces that it has agreed the acquisition of an 80% stake in Thameside West, a landmark waterfront mixed-use development located at the western end of London’s Royal Docks. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117374964/en/ HH Sheikh Sultan bin Ahmed Al Qasimi, Chairman of Arada (centre) with members of the Arada and Keystone executive teams (Photo: AETOSWire) Master-planned by Foster + Partners, the vibrant new urban destination will deliver at least 5,000 homes, with half of the site dedicated to green space and a kilometre of active waterfront. Boasting unrivalled transport links, the integration of air, road, rail, river and tunnel links makes this one of the most connected sites in London. Spread over a 47-acre area – twice the size of the Hudson Yards mixed-use development in New York - Thameside West represents one of Europe’s largest and most strategi

Positive Phase 3 Results Support ZIIHERA® as HER2-Targeted Therapy-of-Choice and Combination with TEVIMBRA® and Chemotherapy as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma17.11.2025 12:00:00 CET | Press release

ZIIHERAplus TEVIMBRA and chemotherapy demonstrated clinically meaningful and statistically significant improvements in PFS and OS versus trastuzumab and chemotherapyZIIHERA plus chemotherapy showed a clinically meaningful and statistically significant improvement in PFS versus trastuzumab and chemotherapy, and a clinically meaningful effect with a strong trend toward statistical significance for OS at the first interim analysisFirst Phase 3 trial in 15 years to demonstrate a clinical benefit in this patient population with a novel HER2-targeted therapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive top-line results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy, with or without PD-1 inhibitor TEVIMBRA® (tislelizumab), as first-line treatment for HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye